BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fatima R, Aziz M. The Hypervirulent Strain of Clostridium Difficile: NAP1/B1/027 - A Brief Overview. Cureus 2019;11:e3977. [PMID: 30967977 DOI: 10.7759/cureus.3977] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Negrut N, Nistor-cseppento DC, Khan SA, Pantis C, Maghiar TA, Maghiar O, Aleya S, Rus M, Tit DM, Aleya L, Rahdar A, Bungau S. Clostridium difficile Infection Epidemiology over a Period of 8 Years—A Single Centre Study. Sustainability 2020;12:4439. [DOI: 10.3390/su12114439] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
2 Hiraki M, Suzuki R, Tanaka N, Fukunaga H, Kinoshita Y, Kimura H, Tsutsui S, Murata M, Morita S. Community-acquired fulminant Clostridioides (Clostridium) difficile infection by ribotype 027 isolate in Japan: a case report. Surg Case Rep 2021;7:137. [PMID: 34101061 DOI: 10.1186/s40792-021-01220-9] [Reference Citation Analysis]
3 Dhungel BA, Govind R. Spo0A Suppresses sin Locus Expression in Clostridioides difficile. mSphere 2020;5:e00963-20. [PMID: 33148827 DOI: 10.1128/mSphere.00963-20] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Kabała M, Gofron Z, Aptekorz M, Sacha K, Harmanus C, Kuijper E, Martirosian G. Clostridioides difficile Ribotype 027 (RT027) Outbreak Investigation Due to the Emergence of Rifampicin Resistance Using Multilocus Variable-Number Tandem Repeat Analysis (MLVA). Infect Drug Resist 2021;14:3247-54. [PMID: 34429622 DOI: 10.2147/IDR.S324745] [Reference Citation Analysis]
5 Usui Y, Nukui Y, Koike R, Tohda S, Saito R. Draft Genome Sequence of a Clostridioides difficile Sequence Type 97 Strain Belonging to Hypervirulent Clade 2. Microbiol Resour Announc 2020;9:e00245-20. [PMID: 32241860 DOI: 10.1128/MRA.00245-20] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Sood N, Carbell G, Greenwald HS, Friedenberg FK. Is the Medium Still the Message? Culture-Independent Diagnosis of Gastrointestinal Infections. Dig Dis Sci 2021. [PMID: 34846676 DOI: 10.1007/s10620-021-07330-6] [Reference Citation Analysis]
7 Genovese C, La Fauci V, D'Amato S, Squeri A, Anzalone C, Costa GB, Fedele F, Squeri R. Molecular epidemiology of antimicrobial resistant microorganisms in the 21th century: a review of the literature. Acta Biomed 2020;91:256-73. [PMID: 32420962 DOI: 10.23750/abm.v91i2.9176] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
8 Wongkuna S, Janvilisri T, Phanchana M, Harnvoravongchai P, Aroonnual A, Aimjongjun S, Malaisri N, Chankhamhaengdecha S. Temporal Variations in Patterns of Clostridioides difficile Strain Diversity and Antibiotic Resistance in Thailand. Antibiotics (Basel) 2021;10:714. [PMID: 34199301 DOI: 10.3390/antibiotics10060714] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Muhammad A, Madhav D, Rawish F, Viveksandeep TC, Albert E, Mollie J, Prateek S. Surotomycin (A Novel Cyclic Lipopeptide) vs. Vancomycin for the Treatment of Clostridioides difficile Infection: A Systematic Review and Meta-analysis. CCP 2019;14:166-74. [DOI: 10.2174/1574884714666190328162637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Waker E, Ambrozkiewicz F, Kulecka M, Paziewska A, Skubisz K, Cybula P, Targoński Ł, Mikula M, Walewski J, Ostrowski J. High Prevalence of Genetically Related Clostridium Difficile Strains at a Single Hemato-Oncology Ward Over 10 Years. Front Microbiol 2020;11:1618. [PMID: 32793147 DOI: 10.3389/fmicb.2020.01618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Muhammad A, Simcha W, Rawish F, Sabih R, Albert E, Ali N. Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis. Curr Clin Pharmacol 2020;15:4-10. [PMID: 31376824 DOI: 10.2174/1574884714666190802124301] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Cebrián R, Macia-Valero A, Jati AP, Kuipers OP. Design and Expression of Specific Hybrid Lantibiotics Active Against Pathogenic Clostridium spp. Front Microbiol 2019;10:2154. [PMID: 31616392 DOI: 10.3389/fmicb.2019.02154] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
13 Obaid NA, Alhifany AA. Clostridioides difficile infections in Saudi Arabia: Where are we standing? Saudi Pharm J 2020;28:1118-21. [PMID: 32922143 DOI: 10.1016/j.jsps.2020.07.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Oka D, Yamaya N, Kuno T, Asakawa Y, Shiragiku T, Chen L, Xue J, Mamuti A, Ye F, Sun J, Ohguro K, Miyamoto H, Uematsu Y, Inagaki K, Cheng JF, Matsumoto M. In Vitro and In Vivo Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile. Antimicrob Agents Chemother 2021;65:e01170-20. [PMID: 33495229 DOI: 10.1128/AAC.01170-20] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Amjad M. An Overview of the Molecular Methods in the Diagnosis of Gastrointestinal Infectious Diseases. Int J Microbiol 2020;2020:8135724. [PMID: 32280346 DOI: 10.1155/2020/8135724] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
16 Kim D, Kim Y, Hwang H, Ciufolini MA, Lee J, Lee H, Clovis S, Jung S, Oh S, Son Y, Kwak J. Nitro-Group-Containing Thiopeptide Derivatives as Promising Agents to Target Clostridioides difficile. Pharmaceuticals 2022;15:623. [DOI: 10.3390/ph15050623] [Reference Citation Analysis]